First Trust Nasdaq Pharmaceuticals ETF
FTXH
19 hedge funds and large institutions have $10.2M invested in First Trust Nasdaq Pharmaceuticals ETF in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 7 closing their positions.
2.71% more ownership
Funds ownership: 46.98% → 49.69% (+2.7%)
21% less capital invested
Capital invested by funds: $12.9M → $10.2M (-$2.75M)
24% less funds holding
Funds holding: 25 → 19 (-6)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPIA
Steward Partners Investment Advisory
New York
|
+$1.1M |
| 2 |
Goldman Sachs
New York
|
+$720K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$329K |
| 4 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$14.1K |
| 5 |
OWA
Outlook Wealth Advisors
Shenandoah,
Texas
|
+$8.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$765K |
| 2 |
PPWM
Paragon Private Wealth Management
Lexington,
Kentucky
|
-$686K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$602K |
| 4 |
WFA
WMG Financial Advisors
Knoxville,
Tennessee
|
-$583K |
| 5 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$568K |
FTXH Hedge Fund Activity: Q3 2023 in Review
19 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q3 2023, worth a combined $10.2M — down 21% from $12.9M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of FTXH and 1 opened new positions — a net loss of 6 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was Steward Partners Investment Advisory, adding an estimated $1.1M. The largest seller was Susquehanna International Group, cutting an estimated $765K.
- 19 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q3 2023, down from 25 in Q2 2023.
- Funds reported $10.2M of First Trust Nasdaq Pharmaceuticals ETF stock for Q3 2023, down 21% quarter-over-quarter.
- 1 fund opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q3 2023 and 7 closed out, a net change of -6 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q3 2023 was Steward Partners Investment Advisory, an estimated $1.1M added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q3 2023 was Susquehanna International Group, an estimated $765K sold.
Based on aggregated 13F filings for Q3 2023.